title: [Aptamer therapeutics].
authors.affiliation: info@ribomic.com
authors.forename: Shin
authors.initials: S
authors.lastname: Miyakawa
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Fujiwara
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Nakamura
mesh_terms: D000818:Animals; D052157:Aptamers, Nucleotide / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015195:Drug Design; D004355:Drug Stability; D039562:Eukaryotic Initiation Factor-4F / Q000235:genetics; D018390:Gene Targeting; D006801:Humans; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use; D010750:Phosphoproteins; D016601:RNA-Binding Proteins; D052156:SELEX Aptamer Technique; D042461:Vascular Endothelial Growth Factor A; D000097796:Nucleolin
chemical_list: D052157:Aptamers, Nucleotide; D039562:Eukaryotic Initiation Factor-4F; D009838:Oligodeoxyribonucleotides; D010750:Phosphoproteins; D016601:RNA-Binding Proteins; D042461:Vascular Endothelial Growth Factor A; D000097796:Nucleolin; C513936:AGRO 100; C467484:VEGFA protein, human; C495058:pegaptanib